347 related articles for article (PubMed ID: 2121721)
1. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
Honsik CJ; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
[TBL] [Abstract][Full Text] [Related]
3. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells.
Lin CC; Shen YC; Chuang CK; Liao SK
Adv Exp Med Biol; 2001; 491():419-29. PubMed ID: 14533812
[TBL] [Abstract][Full Text] [Related]
5. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
6. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
7. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
Chen RL; Reynolds CP; Seeger RC
Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
[TBL] [Abstract][Full Text] [Related]
10. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
12. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
Kushner BH; Cheung NK
Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
Munn DH; Cheung NK
Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
[TBL] [Abstract][Full Text] [Related]
14. Different fine binding specificities of monoclonal antibodies to disialosylganglioside GD2.
Tai T; Kawashima I; Tada N; Dairiki K
J Biochem; 1988 Apr; 103(4):682-7. PubMed ID: 3170507
[TBL] [Abstract][Full Text] [Related]
15. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
Kushner BH; Cheung NK
Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
[TBL] [Abstract][Full Text] [Related]
16. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
[TBL] [Abstract][Full Text] [Related]
17. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
18. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
19. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
Dippold W; Bernhard H
Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
[TBL] [Abstract][Full Text] [Related]
20. New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells.
Gross N; Beck D; Portoukalian J; Favre S; Carrel S
Int J Cancer; 1989 Apr; 43(4):665-71. PubMed ID: 2467885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
